Duell J, Maddocks KJ, González-Barca E, et al. - L-MIND (NCT02399085), an ongoing, open-label, phase 2 study, was performed to evaluate the safety and efficacy of the anti-CD19 antibody tafasitamab + LEN in pts with R/R DLBCL and ECOG status 0–2, who had undergone 1–3 prior systemic therapies (including ≥1 CD20-targeting regimen). Previous work has delineated primary analyses and 2-year efficacy results; researchers herein presented an updated efficacy analysis with ≥ 35 months’ follow-up. Pts were administered 28-day [D] cycles [C] of tafasitamab (12 mg/kg IV), once weekly during C1–3, with a loading dose on D4 of C1, then every 2 weeks (Q2W) during C4–12. On D1–21 of C1–12, patients were administered LEN (25 mg PO). After C12, tafasitamab was administered Q2W to progression-free pts until disease progression. Tafasitamab + LEN was administered to 80 of 81 enrolled pts, and the full analysis set comprised these 80 patients. In pts with R/R DLBCL not eligible for ASCT, combination therapy with tafasitamab + LEN followed by tafasitamab monotherapy yielded durable responses with a median duration of response (DoR) of 43.9 months (NR for pts achieving a CR), along with a manageable safety profile. Considering the long-term data, they suggest that prolonged disease control and survival benefit can be achieved in this pt population by using this chemotherapy-free regimen, especially at first relapse.